DI
XENE icon

Disciplined Investments’s Xenon Pharmaceuticals XENE Stock Holding History

Disciplined Investments’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$39 – 1580
2023
Q2 		$39 Buy
+1
New +$40 ﹤0.01% 1669

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Disciplined Investments's XENE Position: Q3 2023 in Review

Disciplined Investments sold out of Xenon Pharmaceuticals (XENE) in Q3 2023, closing a stake of 1 share — an estimated $39 sold.

Disciplined Investments first reported a position in XENE in Q2 2023 and held it in 1 quarter. The position peaked at $39 in Q2 2023. 180 funds tracked by Wall St. Rank hold XENE as of Q3 2023.

  • Disciplined Investments reported no remaining Xenon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 1 Xenon Pharmaceuticals share in Q3 2023, an estimated $39.
  • Disciplined Investments first reported a position in Xenon Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Disciplined Investments's Xenon Pharmaceuticals position peaked at $39 in Q2 2023.
  • 180 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.